IVD TRIALS at CACLP 2025

Debut at CACLP 2025: IVD TRIALS presents itself as an independent company From March 22 to 24, 2025, IVD TRIALS took part in CACLP, one of Asia’s most important exhibition for clinical diagnostics, held in Nanchang, China.

We would like to sincerely thank all visitors for the inspiring conversations and valuable exchange at our booth. Many discussions focused on regulatory approvals for the EU (IVDR) and WHO Prequalification. There was particular interest in analytes such as HIV, HBV, syphilis, HPV, HTLV, dengue fever, and malaria, underlining the international relevance of our work in clinical studies. A key milestone this year was our first appearance under the new name IVD TRIALS GmbH. Formerly part of BIOMEX, we now operate as an independent company. This new structure allows for greater flexibility and a sharper focus on regulatory-ready IVD studies. The positive feedback we received at CACLP confirmed the strength of this development.

For those who were unable to attend in person, our team at NeckarBiotechnology in Shanghai remains available to support our customers and partners in China. We are already looking forward to continuing the conversation at CACLP 2026.